Crystal Structure of a New Antitumor Compound
Author Information
Author(s): Huang Ting-Ting, Meng Na-Na, Qing Xiao-Yu, Yu Luo-Ting
Primary Institution: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, People’s Republic of China
Hypothesis
The title compound, a derivative of Sorafenib, is expected to have improved anticancer activity.
Conclusion
The study successfully determined the crystal structure of the compound, revealing its potential as a potent antitumor drug.
Supporting Evidence
- The compound showed better in vitro anticancer activity against two tumor cell lines.
- Two independent molecules were found in the asymmetric unit of the crystal structure.
Takeaway
Scientists studied a new medicine that might help fight cancer better than existing ones, and they figured out what it looks like at a tiny level.
Methodology
The compound was synthesized and its crystal structure was analyzed using X-ray diffraction.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website